<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><description>领星是由中美生物医学数据科学家携手高年资肿瘤专家共同开创的临床科技和数据平台，提供肿瘤精准医疗和数据智能服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 28 May 2021 19:44:13 +0800</pubDate><image><url>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</url><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>星学术丨组学技术在肿瘤精准医疗研究中有何应用？</title><link>https://mp.weixin.qq.com/s/JggDOLb4z37JvNNPMJ8hZw</link><description></description><content:encoded><![CDATA[星学术丨组学技术在肿瘤精准医疗研究中有何应用？]]></content:encoded><pubDate>Fri, 28 May 2021 18:16:32 +0800</pubDate></item><item><title>一文盘点侵袭性 B 细胞淋巴瘤中的小分子靶向药物</title><link>https://mp.weixin.qq.com/s/HqMJm0TqgzN4ArXODqDOxg</link><description></description><content:encoded><![CDATA[一文盘点侵袭性 B 细胞淋巴瘤中的小分子靶向药物]]></content:encoded><pubDate>Thu, 27 May 2021 11:08:42 +0800</pubDate></item><item><title>速递丨正大天晴苹果酸舒尼替尼胶囊获批上市；创新RAF/MEK抑制剂获突破性疗法认定</title><link>https://mp.weixin.qq.com/s/yBbJIHLcwgkoPkmh2IZeDg</link><description></description><content:encoded><![CDATA[速递丨正大天晴苹果酸舒尼替尼胶囊获批上市；创新RAF/MEK抑制剂获突破性疗法认定]]></content:encoded><pubDate>Thu, 27 May 2021 11:08:42 +0800</pubDate></item><item><title>星案例丨基因检测指导罕见胃-胰间隙腺鳞癌患者免疫治疗获益</title><link>https://mp.weixin.qq.com/s/HPX5sOj3NzAYlCNVxm1hDw</link><description></description><content:encoded><![CDATA[星案例丨基因检测指导罕见胃-胰间隙腺鳞癌患者免疫治疗获益]]></content:encoded><pubDate>Wed, 26 May 2021 18:12:03 +0800</pubDate></item><item><title>临床试验丨胆管癌</title><link>https://mp.weixin.qq.com/s/w09er2aZdTjIk8E4xWsJtQ</link><description></description><content:encoded><![CDATA[临床试验丨胆管癌]]></content:encoded><pubDate>Wed, 26 May 2021 18:12:03 +0800</pubDate></item><item><title>CheckMate331：纳武单抗二线治疗小细胞肺癌的受挫证据更新！</title><link>https://mp.weixin.qq.com/s/jRZwFoeevSquRCuYN7bH2w</link><description></description><content:encoded><![CDATA[CheckMate331：纳武单抗二线治疗小细胞肺癌的受挫证据更新！]]></content:encoded><pubDate>Tue, 25 May 2021 17:30:34 +0800</pubDate></item><item><title>速递丨拜耳抗癌靶向药Larotrectinib胶囊上市申请获受理</title><link>https://mp.weixin.qq.com/s/2GJEEU5JZApwvl2cAy-Lqg</link><description></description><content:encoded><![CDATA[速递丨拜耳抗癌靶向药Larotrectinib胶囊上市申请获受理]]></content:encoded><pubDate>Tue, 25 May 2021 17:30:34 +0800</pubDate></item><item><title>预告丨领星与安捷伦强强联合，探讨捕获测序在肿瘤精准医疗和研究中的应用</title><link>https://mp.weixin.qq.com/s/FOd-gRhQHbc4q8xxuw1H9w</link><description></description><content:encoded><![CDATA[预告丨领星与安捷伦强强联合，探讨捕获测序在肿瘤精准医疗和研究中的应用]]></content:encoded><pubDate>Thu, 20 May 2021 11:28:28 +0800</pubDate></item><item><title>速递丨转移性乳腺癌新药！卫材公布Halaven真实世界研究强劲疗效数据</title><link>https://mp.weixin.qq.com/s/-4fQL6AAK1PUFnk00BCq3A</link><description></description><content:encoded><![CDATA[速递丨转移性乳腺癌新药！卫材公布Halaven真实世界研究强劲疗效数据]]></content:encoded><pubDate>Thu, 20 May 2021 11:28:28 +0800</pubDate></item><item><title>临床试验丨 肝癌（五）</title><link>https://mp.weixin.qq.com/s/Ke5iQ2TBXN-o4sBUW1fH3A</link><description></description><content:encoded><![CDATA[临床试验丨 肝癌（五）]]></content:encoded><pubDate>Wed, 19 May 2021 11:21:00 +0800</pubDate></item><item><title>纳武单抗能用于食管癌及胃食管癌术后辅助化疗吗？</title><link>https://mp.weixin.qq.com/s/h9UIIXFa_nrGDzWPBkwxfA</link><description></description><content:encoded><![CDATA[纳武单抗能用于食管癌及胃食管癌术后辅助化疗吗？]]></content:encoded><pubDate>Tue, 18 May 2021 16:32:38 +0800</pubDate></item><item><title>速递丨云顶新耀戈沙妥组单抗(Trodelvy)上市申请获国家药监局受理!</title><link>https://mp.weixin.qq.com/s/i4YUmL94VhYjiP8hqPuw5g</link><description></description><content:encoded><![CDATA[速递丨云顶新耀戈沙妥组单抗(Trodelvy)上市申请获国家药监局受理!]]></content:encoded><pubDate>Tue, 18 May 2021 16:32:38 +0800</pubDate></item><item><title>一文梳理CAR-T 细胞治疗多发性骨髓瘤临床应用证据</title><link>https://mp.weixin.qq.com/s/k9gVGFCAz1jxxpXc-umjgA</link><description></description><content:encoded><![CDATA[一文梳理CAR-T 细胞治疗多发性骨髓瘤临床应用证据]]></content:encoded><pubDate>Thu, 13 May 2021 11:48:17 +0800</pubDate></item><item><title>速递丨Nat Med：揭示乳腺癌免疫治疗作用机制并提出预测疗效新方法</title><link>https://mp.weixin.qq.com/s/CNs2ielMhaRIWj9Q_7qTsg</link><description></description><content:encoded><![CDATA[速递丨Nat Med：揭示乳腺癌免疫治疗作用机制并提出预测疗效新方法]]></content:encoded><pubDate>Thu, 13 May 2021 11:48:17 +0800</pubDate></item><item><title>临床试验丨 肝癌（四）</title><link>https://mp.weixin.qq.com/s/1msE45Ba-JmSxhJI05nWXQ</link><description></description><content:encoded><![CDATA[临床试验丨 肝癌（四）]]></content:encoded><pubDate>Wed, 12 May 2021 07:54:57 +0800</pubDate></item><item><title>液体活检监测MRD为何如此重要？</title><link>https://mp.weixin.qq.com/s/TApCEh3TDhs09r5Eg7xdvg</link><description></description><content:encoded><![CDATA[液体活检监测MRD为何如此重要？]]></content:encoded><pubDate>Tue, 11 May 2021 18:25:34 +0800</pubDate></item><item><title>速递丨博安生物贝伐珠单抗注射液在华获批上市</title><link>https://mp.weixin.qq.com/s/x51ZGYPHtvzgkH4oRWJUZg</link><description></description><content:encoded><![CDATA[速递丨博安生物贝伐珠单抗注射液在华获批上市]]></content:encoded><pubDate>Tue, 11 May 2021 18:25:34 +0800</pubDate></item></channel></rss>